Healthcare / BiotechnologyTokyo
$150.00
+1.00 (+0.67%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 16%
FCF escenarios
weak_data · normalized FCF $-453.6M · quality 37.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
19/100
F
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$7.4B
P/E
N/A
•EV/EBITDA
42.3x
↑ROE
-1.5%
↓Gross Margin
32.3%
↓Debt/Equity
1.30
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+48.0%
FCF CAGR
—
FCF margin
18.3%
FCF / Net income
-44.00x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $5.08B · net income $-21.1M · FCF $930.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $5.08B | $5.08B | $2.43B | $2.78B | $1.57B |
| Net Income | $-21.1M | $-21.1M | $-1.42B | $-657.4M | $-550.9M |
| EBITDA | $116.3M | $116.3M | $-1.38B | $-620.5M | $-531.9M |
| EPS | -0.52 | -0.52 | -40.23 | -20.77 | -17.86 |
| Gross Margin | 32.3% | 32.3% | 42.8% | 55.0% | 64.9% |
| Operating Margin | 0.5% | 0.5% | -54.9% | -19.8% | -41.5% |
| Net Margin | -0.4% | -0.4% | -58.5% | -23.7% | -35.1% |
| Balance Sheet | |||||
| Debt/Equity | 1.30 | 1.30 | 3.10 | 1.58 | 0.41 |
| Current Ratio | 2.72 | 2.72 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $930.3M | $930.3M | $-453.6M | $-1.42B | $-1.17B |
| Returns | |||||
| ROE | -1.5% | -1.5% | -171.0% | -53.3% | -32.3% |
| Valuation | |||||
| EV/EBITDA | 42.30 | 42.30 | — | — | — |
| P/B | 4.31 | 4.31 | 5.78 | 6.34 | 8.41 |
| Growth & Yield | |||||
| Revenue Growth | 109.0% | 109.0% | -12.4% | 76.9% | — |
| EPS Growth | 98.7% | 98.7% | -93.7% | -16.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-12.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-40.23 → -0.52
Residual
-12.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.